Autolus Therapeutics (AUTL) Cash from Operations (2017 - 2025)

Autolus Therapeutics' Cash from Operations history spans 6 years, with the latest figure at 67323000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 77.47% year-over-year to 67323000.0; the TTM value through Dec 2025 reached 283568000.0, down 37.47%, while the annual FY2025 figure was 283568000.0, 37.47% down from the prior year.
  • Cash from Operations reached 67323000.0 in Q4 2025 per AUTL's latest filing, up from 67899000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 14566000.0 in Q4 2022 to a low of 76740000.0 in Q3 2024.
  • Average Cash from Operations over 4 years is 49999384.62, with a median of 42419000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: tumbled 90.95% in 2024, then rose 11.52% in 2025.
  • A 4-year view of Cash from Operations shows it stood at 14566000.0 in 2022, then plummeted by 70.49% to 24833000.0 in 2023, then tumbled by 52.76% to 37934000.0 in 2024, then tumbled by 77.47% to 67323000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Cash from Operations are 67323000.0 (Q4 2025), 67899000.0 (Q3 2025), and 72781000.0 (Q2 2025).